Achromatopsia Market Pipeline Review, H1 2016

Hexa Reports
Market Research Reports and Insightful Company Profiles
Achromatopsia Market Size, Share, Treatment, Symptoms,
Global Insights, Trends and Growth, Causes, Pipeline
Review, H1 2016
Summary
Global Markets Direct's, 'Achromatopsia - Pipeline Review, H1 2016', provides an overview of the
Achromatopsia pipeline landscape.
The report provides comprehensive information on the therapeutics under development for
Achromatopsia, complete with analysis by stage of development, drug target, mechanism of action
(MoA), route of administration (RoA) and molecule type. The report also covers the descriptive
pharmacological action of the therapeutics, its complete research and development history and latest
news and press releases. Additionally, the report provides an overview of key players involved in
therapeutic development for Achromatopsia and features dormant and discontinued projects.
Browse Detail Report With TOC @ http://www.hexareports.com/report/achromatopsia-pipelinereview-h1-2016/details
Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy
areas and nearly 3,000 indications. The report is built using data and information sourced from Global
Markets Direct's proprietary databases, company/university websites, clinical trial registries,
conferences, SEC filings, investor presentations and featured press releases from company/university
sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic
review following a stringent set of processes to ensure that all the profiles are updated with the latest
Hexa Reports
Market Research Reports and Insightful Company Profiles
set of information. Additionally, various dynamic tracking processes ensure that the most recent
developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios,
enhances decision making capabilities and helps to create effective counter strategies to gain
competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance
of data.
Scope
- The report provides a snapshot of the global therapeutic landscape of Achromatopsia
- The report reviews pipeline therapeutics for Achromatopsia by companies and universities/research
institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from preregistration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product
description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental
activities
- The report reviews key players involved Achromatopsia therapeutics and enlists all their major and
minor projects
- The report assesses Achromatopsia therapeutics based on drug target, mechanism of action (MoA),
route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Achromatopsia
Reasons To Buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D
strategies
- Identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for
Achromatopsia
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline
therapeutics
- Devise corrective measures for pipeline projects by understanding Achromatopsia pipeline depth and
focus of Indication therapeutics
Hexa Reports
Market Research Reports and Insightful Company Profiles
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with
the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors
that drove them from pipeline
Request A Sample copy of This Report @ http://www.hexareports.com/sample/135403
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Achromatopsia Overview 7
Therapeutics Development 8
Pipeline Products for Achromatopsia - Overview 8
Achromatopsia - Therapeutics under Development by Companies 9
Achromatopsia - Pipeline Products Glance 10
Clinical Stage Products 10
Early Stage Products 11
Achromatopsia - Products under Development by Companies 12
Achromatopsia - Companies Involved in Therapeutics Development 13
Amgen Inc. 13
Applied Genetic Technologies Corporation 14
Achromatopsia - Therapeutics Assessment 15
Assessment by Monotherapy Products 15
Assessment by Route of Administration 16
Assessment by Molecule Type 17
Drug Profiles 19
Gene Therapy for Achromatopsia - Drug Profile 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
Gene Therapy for X-linked retinoschisis and Achromatopsia - Drug Profile 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
Gene Therapy to Activate CNGA3 for Achromatopsia - Drug Profile 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
Hexa Reports
Market Research Reports and Insightful Company Profiles
Browse Full
2016/details
Report
@
http://www.hexareports.com/report/achromatopsia-pipeline-review-h1-
About Us:
Hexa Reports is a market research and consulting organization, offering industry reports, custom
research and consulting services to a host of key industries across the globe. We offer comprehensive
business intelligence in the form of industry reports which help our clients obtain clarity about their
business environment and enable them to undertake strategic growth initiatives.
Contact Information:
Ryan Shaw
Felton Office Plaza,
6265 Highway 9,
Felton, California, 95018,
United States
Phone Number
1-800-489-3075
Email Us: sales@hexareports.com
Our Website: http://www.hexareports.com/
Visit Our Blogs: http://hexareports.blogspot.in